8-K: Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Prime Medicine is on track to report initial data from its Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 and expects to file an IND and/or CTA for PM577 for Wilson's Disease in the first half of 2026.

Summary

• Prime Medicine reported its full-year 2024 financial results and provided a business update.
• The company is on track to report initial data from the Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025.
• IND-enabling studies are ongoing for PM577 for Wilson's Disease, with an expected IND and/or CTA filing in the first half of 2026.
• Research and Development expenses were $155.3 million for the year ended December 31, 2024, compared to $147.9 million for the year ended December 31, 2023.
• General and Administrative expenses were $50.2 million for the year ended December 31, 2024, compared to $43.4 million for the year ended December 31, 2023.
• Net loss was $195.9 million for the year ended December 31, 2024, compared to $198.1 million for the year ended December 31, 2023.
• As of December 31, 2024, cash, cash equivalents, investments, and restricted cash were $204.5 million, compared to $135.2 million as of December 31, 2023.
• The company expects its cash, cash equivalents, and investments will be sufficient to fund operating expenses and capital expenditure requirements into the first half of 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is progressing its clinical programs and has sufficient cash to fund operations into the first half of 2026. However, the company is still incurring significant losses.

Positives

• Prime Medicine is on track to report initial data from its Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025.
• The company expects to file an IND and/or CTA for PM577 for Wilson's Disease in the first half of 2026.
• The company's cash position of $204.5 million is expected to fund operations into the first half of 2026.

Negatives

• The company reported a net loss of $195.9 million for the year ended December 31, 2024.
• Research and Development expenses increased to $155.3 million for the year ended December 31, 2024.
• General and Administrative expenses increased to $50.2 million for the year ended December 31, 2024.

Risks

• The company's future performance is subject to risks associated with uncertainties related to product candidates entering clinical trials.
• There are risks related to the development and optimization of new technologies.
• The company's future performance is subject to risks related to the scope of protection Prime Medicine is able to establish and maintain for intellectual property rights covering its Prime Editing technology.
• The company's future performance is subject to risks related to Prime Medicines expectations regarding the anticipated timeline of its cash runway and future financial performance.

Future Outlook

Prime Medicine expects its current cash, cash equivalents, and investments will be sufficient to fund its operating expenses and capital expenditure requirements into the first half of 2026.

Management Comments

• Entering 2025 marks the next chapter for Prime Medicine as we look to share initial data for our most advanced product candidate, PM359, in chronic granulomatous disease, the only Prime Editor currently in clinical development, said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine.
• If positive, we believe this readout will be a watershed moment for our company, validating Prime Editings differentiated safety profile and curative potential.
• Dr. Gottesdiener added, In parallel, we are advancing our Prime Editors for Wilsons Disease and Cystic Fibrosis.
• We are particularly encouraged by recent progress in Wilsons Disease, a program that we believe will be a fundamental driver of our long-term growth and remains on-track for clinical entry in 2026.
• We look forward to sharing new in vivo data from across our preclinical programs in 2025 as we continue to accelerate our pipeline through both internal efforts and additional strategic partnerships.

Industry Context

Prime Medicine is operating in the competitive gene editing therapy space, focusing on hematology, immunology, oncology, liver, and lung diseases. The company's progress with Prime Editing technology and its clinical programs positions it among other companies developing gene therapies for genetic diseases.

Comparison to Industry Standards

• Prime Medicine's approach to gene editing with its Prime Editing platform is comparable to other gene editing companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, which are also developing therapies for genetic diseases.
• The company's focus on specific diseases like CGD, Wilson's Disease, and Cystic Fibrosis aligns with the industry trend of targeting diseases with well-understood biology and clear clinical development paths.
• The expected timeline for clinical entry of PM577 in 2026 is within the typical development timeline for gene therapy programs, but the actual speed of development will be a key factor in its competitive positioning.

Related Party Transactions

• Collaboration revenue related party was $1,609 thousand for the year ended December 31, 2024.
• Settlement payment related party was $13,500 thousand for the year ended December 31, 2024.
• Change in fair value of short-term investment related party was $(485) thousand for the year ended December 31, 2024.

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and financial stability are positive for shareholders.
• Employees: The company's continued operations and pipeline development provide job security and growth opportunities for employees.
• Patients: The company's development of gene editing therapies offers potential curative treatments for genetic diseases.

Next Steps

• Announce initial clinical data from Cohort 1 in Phase 1/2 trial of PM359 for p47phox CGD in 2025.
• Advance PM577 through investigational new drug (IND)-enabling studies for the treatment of Wilsons Disease patients with the most prevalent Wilsons Disease mutation in the United States.
• File IND and/or clinical trial application for PM577 in the first half of 2026.

Key Dates